Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2019-06-27
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 37
- Registration Number
- NCT04000282
- Locations
- 🇨🇿
Investigational Site Number : 2030002, Brno, Czechia
🇨🇿Investigational Site Number : 2030003, Ostrava - Poruba, Czechia
🇺🇸City of Hope Site Number : 8400002, Duarte, California, United States
Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis
- First Posted Date
- 2019-06-24
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 125
- Registration Number
- NCT03996291
- Locations
- 🇺🇸
North Central Neurology Associates, PC Site Number : 8400005, Cullman, Alabama, United States
🇺🇸Neurology Associates, PA Site Number : 8400002, Maitland, Florida, United States
🇺🇸University of South Florida Site Number : 8400009, Tampa, Florida, United States
Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 955
- Registration Number
- NCT03992417
- Locations
- 🇧🇪
Investigational Site Number : 0560010, Gent, Belgium
🇨🇴Investigational Site Number : 1700008, Bogota, Colombia
🇧🇪Investigational Site Number : 0560004, Namur, Belgium
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Inhaled CorticosteroidDrug: Inhaled Long-Acting Beta AgonistDrug: PlaceboDrug: Inhaled Long-Acting Muscarinic Antagonist
- First Posted Date
- 2019-04-29
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 939
- Registration Number
- NCT03930732
- Locations
- 🇨🇦
Investigational Site Number :1240013, Windsor, Ontario, Canada
🇨🇦Investigational Site Number :1240021, Edmonton, Alberta, Canada
🇨🇳Investigational Site Number :1560037, Baotou, China
Comparison of Exposure and Activity of SAR341402 Mix 70/30 to NovoLog Mix 70/30, NovoMix 30 and SAR341402 Rapid-acting Solution in Patients With Type 1 Diabetes Mellitus
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 52
- Registration Number
- NCT03916601
- Locations
- 🇩🇪
Investigational Site Number 2760001, Neuss, Germany
Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- First Posted Date
- 2019-04-11
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 165
- Registration Number
- NCT03912259
- Locations
- 🇨🇳
Investigational Site Number 1560006, Changsha, China
🇨🇳Investigational Site Number 1560030, Lianyungang, China
🇨🇳Investigational Site Number 1560021, Changchun, China
Sotagliflozin Multiple-dose Study in Healthy Chinese Subjects
- Conditions
- Diabetes Mellitus
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-04-10
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 24
- Registration Number
- NCT03909451
- Locations
- 🇨🇳
Investigational Site Number 1560001, Beijing, China
A Bioequivalence Study Comparing Two Different Strengths Formulations of Insulin Lispro in Patients With Type 1 Diabetes
- Conditions
- Type 1 Diabetes
- Interventions
- Drug: Insulin Lispro SAR342434
- First Posted Date
- 2019-04-04
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 90
- Registration Number
- NCT03903016
- Locations
- 🇩🇪
Investigational Site Number 2760001, Neuss, Germany
Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Drug: PlaceboDrug: Locally approved intravenous contrast medium for contrast enhanced magnetic resonance imaging (MRI)
- First Posted Date
- 2019-03-26
- Last Posted Date
- 2023-03-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 130
- Registration Number
- NCT03889639
- Locations
- 🇺🇸
Investigational Site Number 8400005, Cullman, Alabama, United States
🇺🇸Investigational Site Number 8400002, Maitland, Florida, United States
🇺🇸Investigational Site Number 8400004, Sunrise, Florida, United States
Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- First Posted Date
- 2019-03-14
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 210
- Registration Number
- NCT03874715
- Locations
- 🇺🇸
Investigational Site Number 8400014, Concord, California, United States
🇺🇸Investigational Site Number 8400038, Doral, Florida, United States
🇺🇸Investigational Site Number 8400027, Houston, Texas, United States